Pediatrix Medical Group, Inc. (NYSE:MD) Shares Acquired by Rubric Capital Management LP

Rubric Capital Management LP grew its stake in Pediatrix Medical Group, Inc. (NYSE:MD) by 1.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,275,000 shares of the company’s stock after purchasing an additional 125,000 shares during the period. Pediatrix Medical Group comprises approximately 1.6% of Rubric Capital Management LP’s investment portfolio, making the stock its 12th largest holding. Rubric Capital Management LP owned 9.64% of Pediatrix Medical Group worth $95,907,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of MD. Aristeia Capital L.L.C. purchased a new stake in shares of Pediatrix Medical Group in the 2nd quarter valued at $687,000. Vanguard Group Inc. lifted its holdings in Pediatrix Medical Group by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 10,557,572 shares of the company’s stock worth $105,892,000 after buying an additional 164,333 shares during the last quarter. Boston Partners boosted its holdings in Pediatrix Medical Group by 34.0% in the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after purchasing an additional 453,254 shares in the last quarter. Principal Financial Group Inc. increased its stake in Pediatrix Medical Group by 14.1% in the third quarter. Principal Financial Group Inc. now owns 513,618 shares of the company’s stock valued at $5,953,000 after purchasing an additional 63,581 shares during the last quarter. Finally, ClariVest Asset Management LLC purchased a new stake in shares of Pediatrix Medical Group during the 2nd quarter worth approximately $1,721,000. Hedge funds and other institutional investors own 97.71% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on MD. Jefferies Financial Group boosted their price target on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research note on Monday, November 4th. StockNews.com cut shares of Pediatrix Medical Group from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. UBS Group raised their price target on Pediatrix Medical Group from $10.50 to $16.50 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, Truist Financial increased their price objective on Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $16.10.

Insiders Place Their Bets

In other Pediatrix Medical Group news, EVP Mary Ann E. Moore sold 8,108 shares of Pediatrix Medical Group stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the transaction, the executive vice president now directly owns 135,810 shares of the company’s stock, valued at $2,172,960. The trade was a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Mark S. Ordan sold 27,600 shares of the stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the sale, the director now owns 138,683 shares of the company’s stock, valued at approximately $2,128,784.05. This trade represents a 16.60 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 46,808 shares of company stock worth $673,157. 1.20% of the stock is owned by corporate insiders.

Pediatrix Medical Group Price Performance

MD opened at $14.76 on Wednesday. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42. Pediatrix Medical Group, Inc. has a 12 month low of $6.62 and a 12 month high of $16.41. The stock has a market capitalization of $1.27 billion, a P/E ratio of -4.82, a P/E/G ratio of 2.10 and a beta of 1.55. The business has a 50 day simple moving average of $13.01 and a 200-day simple moving average of $10.10.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings results on Friday, November 1st. The company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The business had revenue of $511.20 million for the quarter, compared to analysts’ expectations of $498.87 million. During the same period in the prior year, the company posted $0.29 EPS. The business’s revenue for the quarter was up .9% on a year-over-year basis. On average, equities analysts anticipate that Pediatrix Medical Group, Inc. will post 1.26 earnings per share for the current fiscal year.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.